BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 59 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,491,355 | -21.2% | 20,083,000 | -20.2% | 0.10% | -17.2% |
| Q2 2023 | $24,741,726 | -4.2% | 25,154,000 | -0.2% | 0.12% | -3.2% |
| Q1 2023 | $25,835,915 | +10.7% | 25,207,000 | +14.8% | 0.13% | +15.6% |
| Q4 2022 | $23,333,982 | +5.8% | 21,949,000 | -1.2% | 0.11% | +7.9% |
| Q3 2022 | $22,046,000 | +169484.6% | 22,216,000 | +170792.3% | 0.10% | – |
| Q2 2022 | $13,000 | – | 13,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |